Pharmaceutical Opening the door to wider treatment access and faster adoption of oral therapies for obstructive sleep apnea (OSA) and other sleep-related breathing diseases, Cambridge, USA-based Apnimed has acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Germany’s Desitin Arzneimittel. 28 April 2025